HK1000303A1 - Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses - Google Patents

Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses Download PDF

Info

Publication number
HK1000303A1
HK1000303A1 HK97101841A HK97101841A HK1000303A1 HK 1000303 A1 HK1000303 A1 HK 1000303A1 HK 97101841 A HK97101841 A HK 97101841A HK 97101841 A HK97101841 A HK 97101841A HK 1000303 A1 HK1000303 A1 HK 1000303A1
Authority
HK
Hong Kong
Prior art keywords
groups
group
carbon atoms
methyl
substituted
Prior art date
Application number
HK97101841A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1000303B (en
Inventor
Kojima Koichi
Kurata Hitoshi
Ishibashi Koki
Hamada Takakazu
Horikoshi Hiroyoshi
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of HK1000303B publication Critical patent/HK1000303B/en
Publication of HK1000303A1 publication Critical patent/HK1000303A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK97101841A 1992-04-20 1997-09-25 Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses HK1000303A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9981692 1992-04-20
JP99816/92 1992-04-20
JP32804392 1992-12-08
JP328043/92 1992-12-08

Publications (2)

Publication Number Publication Date
HK1000303B HK1000303B (en) 1998-02-20
HK1000303A1 true HK1000303A1 (en) 1998-02-20

Family

ID=26440917

Family Applications (1)

Application Number Title Priority Date Filing Date
HK97101841A HK1000303A1 (en) 1992-04-20 1997-09-25 Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses

Country Status (25)

Country Link
US (3) US5536714A (enExample)
EP (2) EP0567271B1 (enExample)
JP (1) JP2514778B2 (enExample)
KR (1) KR0146680B1 (enExample)
CN (2) CN1041095C (enExample)
AT (1) ATE154937T1 (enExample)
AU (1) AU656852B2 (enExample)
CA (1) CA2094300C (enExample)
CZ (2) CZ283791B6 (enExample)
DE (1) DE69311837T2 (enExample)
DK (1) DK0567271T3 (enExample)
ES (1) ES2105108T3 (enExample)
FI (1) FI931765L (enExample)
GR (1) GR3024896T3 (enExample)
HK (1) HK1000303A1 (enExample)
HU (1) HU219579B (enExample)
ID (1) ID18576A (enExample)
IL (1) IL105478A (enExample)
MX (1) MX9302300A (enExample)
NO (1) NO304891B1 (enExample)
NZ (1) NZ247449A (enExample)
PH (1) PH31052A (enExample)
RU (2) RU2114861C1 (enExample)
TW (2) TW238312B (enExample)
ZA (1) ZA932732B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
KR950701340A (ko) * 1992-04-30 1995-03-23 스튜어트 알. 슈터 17알파 및 17베타-치환된 에스트라-1,3,5,(10)-트리엔-3-카르복실산(17α AND 17β-SUBSTITUTED ESTRA-1,2,3(10)-TRIENE-3-CARBOXYLIC ACID)
GB9224148D0 (en) * 1992-11-18 1993-01-06 Smithkline Beecham Corp Compounds
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
JPH09504271A (ja) * 1993-09-03 1997-04-28 スミスクライン・ビーチャム・コーポレイション 安定した錠剤処方
GB9324371D0 (en) * 1993-11-26 1994-01-12 Erba Carlo Spa Side chain fluoro substituted 3-carboxysteroids
GB9411103D0 (en) * 1994-06-03 1994-07-27 Smithkline Beecham Corp Compounds
GB9415183D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 3-carboxysteroids with a fluorinated side-chain
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
WO2003029268A1 (en) * 2001-10-03 2003-04-10 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
AU2002361861A1 (en) * 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US7604386B2 (en) * 2005-11-18 2009-10-20 Federal-Mogul World Wide, Inc Lamp assembly having a socket made from high temperature plastic
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US8563728B2 (en) * 2009-07-09 2013-10-22 Aurobindo Pharma Ltd. Process for the preparation of Dutasteride
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors

Also Published As

Publication number Publication date
JPH06279487A (ja) 1994-10-04
CA2094300A1 (en) 1993-10-21
RU2097387C1 (ru) 1997-11-27
US5536714A (en) 1996-07-16
CZ284206B6 (cs) 1998-09-16
CN1195666A (zh) 1998-10-14
CN1041095C (zh) 1998-12-09
GR3024896T3 (en) 1998-01-30
IL105478A0 (en) 1993-08-18
EP0567271B1 (en) 1997-07-02
AU656852B2 (en) 1995-02-16
HU219579B (hu) 2001-05-28
DE69311837T2 (de) 1998-02-12
DE69311837D1 (de) 1997-08-07
TW401420B (en) 2000-08-11
ZA932732B (en) 1993-10-28
NO304891B1 (no) 1999-03-01
HU9301155D0 (en) 1993-07-28
IL105478A (en) 1998-03-10
KR930021654A (ko) 1993-11-22
CN1083070A (zh) 1994-03-02
KR0146680B1 (ko) 1998-08-01
CA2094300C (en) 2003-01-28
FI931765A7 (fi) 1993-10-21
CZ283791B6 (cs) 1998-06-17
FI931765A0 (fi) 1993-04-19
ATE154937T1 (de) 1997-07-15
PH31052A (en) 1998-02-03
EP0567271A2 (en) 1993-10-27
US5760025A (en) 1998-06-02
RU2114861C1 (ru) 1998-07-10
ID18576A (id) 1998-04-23
DK0567271T3 (da) 1998-02-16
AU3698493A (en) 1993-10-21
EP0567271A3 (en) 1994-11-23
JP2514778B2 (ja) 1996-07-10
FI931765L (fi) 1993-10-21
EP0725074A2 (en) 1996-08-07
NO931401D0 (no) 1993-04-16
US5717088A (en) 1998-02-10
NO931401L (no) 1993-10-21
TW238312B (enExample) 1995-01-11
NZ247449A (en) 1995-02-24
CZ90097A3 (cs) 1998-07-15
CZ67893A3 (en) 1994-01-19
RU95101838A (ru) 1997-01-10
MX9302300A (es) 1994-03-31
HUT64558A (en) 1994-01-28
ES2105108T3 (es) 1997-10-16
EP0725074A3 (en) 1996-11-20

Similar Documents

Publication Publication Date Title
EP0567271B1 (en) Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses
HK1000303B (en) Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses
US5155107A (en) 17β-substituted-4-aza-5α-androstan-3-one derivatives and process for their preparation
EP0484094B1 (en) Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
US5359071A (en) 15-substituted 4-azasteroids
RU2125061C1 (ru) ФТОРИРОВАННЫЕ ПРОИЗВОДНЫЕ 17β-ЗАМЕЩЕННОГО -4-АЗА-5α-АНДРОСТАН-3-ОНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
EP0649431B1 (en) 17-amino substituted 4-azasteroid 5-alpha-reductase inhibitors
US5595996A (en) 7-substituted 4-aza cholanic acid derivatives and their use
EP0540717B1 (en) UNSATURATED 17$g(b)-SUBSTITUTED 3-CARBOXY STEROIDS
US5698720A (en) Steroid derivatives
JP3031585B2 (ja) Ｃ▲１７−２０▼リアーゼ抑制法におけるアミノステロイド類
JPH10501233A (ja) ５アルファレダクターゼの処理用ステロイド誘導体
HK1005456B (en) Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
HK1011693B (en) Fluorinated 17-beta substituted-4-aza-5-alpha-andostran-3one derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)